Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Albendazole 400 mg in Healthy Adults
NCT06201559Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of albendazole in intestinal diseases (2 arms), sponsored by GSK. Primary endpoints: Maximum Plasma Concentration of Albendazole at 24 hours and Area Under the Plasma Concentration Curve From Time 0 to Last Measured at 24 hours. Started Aug 2023; status: completed.
02
Drugs
albendazole
03
Conditions
intestinal diseases
Beyond the preview
Go deeper on NCT06201559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201559.